Literature DB >> 9634700

Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.

Y Xue1, P Björquist, T Inghardt, M Linschoten, D Musil, L Sjölin, J Deinum.   

Abstract

BACKGROUND: Plasminogen activator inhibitor type 1 (PAI-1) is an important endogenous regulator of the fibrinolytic system. Reduction of PAI-1 activity has been shown to enhance dissolution of blood clots. Like other serpins, PAI-1 binds covalently to a target serine protease, thereby irreversibly inactivating the enzyme. During this process the exposed reactive-centre loop of PAI-1 is believed to undergo a conformational change becoming inserted into beta sheet A of the serpin. Incubation with peptides from the reactive-centre loop transform serpins into a substrate for their target protease. It has been hypothesised that these peptides bind to beta sheet A, thereby hindering the conformational rearrangement leading to loop insertion and formation of the stable serpin-protease complex.
RESULTS: We report here the 1.95 A X-ray crystal structure of a complex of a glycosylated mutant of PAI-1, PAI-1-ala335Glu, with two molecules of the inhibitory reactive-centre loop peptide N-Ac-TVASS-NH2. Both bound peptide molecules are located between beta strands 3A and 5A of the serpin. The binding kinetics of the peptide inhibitor to immobilised PAI-1-Ala335Glu, as monitored by surface plasmon resonance, is consistent with there being two different binding sites.
CONCLUSIONS: This is the first reported crystal structure of a complex formed between a serpin and a serpin inhibitor. The localisation of the inhibitory peptide in the complex strongly supports the theory that molecules binding in the space between beta strands 3A and 5A of a serpin are able to prevent insertion of the reactive-centre loop into beta sheet A, thereby abolishing the ability of the serpin to irreversibly inactivate its target enzyme. The characterisation of the two binding sites for the peptide inhibitor provides a solid foundation for computer-aided design of novel, low molecular weight PAI-1 inhibitors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9634700     DOI: 10.1016/s0969-2126(98)00064-1

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  16 in total

1.  Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.

Authors:  Ashley A Reinke; Shih-Hon Li; Mark Warnock; Maxim E Shaydakov; Naga Sandhya Guntaka; Enming J Su; Jose A Diaz; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2018-12-03       Impact factor: 5.157

2.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

3.  Serpin latency transition at atomic resolution.

Authors:  Giorgia Cazzolli; Fang Wang; Silvio a Beccara; Anne Gershenson; Pietro Faccioli; Patrick L Wintrode
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

4.  Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.

Authors:  Zhonghui Lin; Longguang Jiang; Cai Yuan; Jan K Jensen; Xu Zhang; Zhipu Luo; Barbara C Furie; Bruce Furie; Peter A Andreasen; Mingdong Huang
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

Review 5.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

6.  Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Authors:  Shih-Hon Li; Ashley A Reinke; Karen L Sanders; Cory D Emal; James C Whisstock; Jeanne A Stuckey; Daniel A Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

7.  Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.

Authors:  Ola Fjellström; Johanna Deinum; Tove Sjögren; Carina Johansson; Stefan Geschwindner; Viveca Nerme; Anne Legnehed; Jane McPheat; Karolina Olsson; Cristian Bodin; Amalia Paunovic; David Gustafsson
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

8.  Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Authors:  Shih-Hon Li; Natalia V Gorlatova; Daniel A Lawrence; Bradford S Schwartz
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

9.  Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.

Authors:  Tihami Qureshi; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-11-25       Impact factor: 6.725

10.  Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.

Authors:  Katrine E Pedersen; Anja P Einholm; Anni Christensen; Lotte Schack; Troels Wind; John M Kenney; Peter A Andreasen
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.